|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 309.20 SEK | +1.64% |
|
+2.66% | +15.81% |
| 11-29 | Di: These seven hard-to-get stocks to buy according to the experts | FW |
| 11-25 | Danske Bank Upgrades Sobi to Buy, Lifts PT | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site
| Capitalization | 104B 9.56B 9.08B 8.44B 7.52B 13.45B 810B 14.85B 38.83B 332B 35.9B 35.11B 1,435B | P/E ratio 2024 * |
29.9x | P/E ratio 2025 * | 21.6x |
|---|---|---|---|---|---|
| Enterprise value | 119B 10.86B 10.32B 9.6B 8.54B 15.29B 920B 16.88B 44.13B 378B 40.8B 39.91B 1,631B | EV / Sales 2024 * |
4.66x | EV / Sales 2025 * | 4.01x |
| Free-Float |
51.66% | Yield 2024 * |
-
| Yield 2025 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Swedish Orphan Biovitrum AB
More recommendations
More press releases
More news
| 1 day | +1.64% | ||
| 1 week | +0.45% | ||
| Current month | +2.25% | ||
| 1 month | -7.76% | ||
| 3 months | -0.13% | ||
| 6 months | +8.72% | ||
| Current year | +15.81% |
1 week
299.60
310.40
1 month
286.80336.60
Current year
243.20354.40
1 year
236.40354.40
3 years
169.45354.40
5 years
127.10354.40
10 years
73.10354.40
| Director | Title | Age | Since |
|---|---|---|---|
Guido Oelkers
CEO | Chief Executive Officer | 59 | 21/05/2017 |
Henrik Stenqvist
DFI | Director of Finance/CFO | 57 | 19/07/2018 |
| Chief Tech/Sci/R&D Officer | 53 | - |
| Manager | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | 04/05/2011 | |
Annette Clancy
CHM | Chairman | 70 | 04/01/2024 |
Staffan Schüberg
BRD | Director/Board Member | 55 | 31/12/2019 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.15% | 228 M€ | +9.61% | ||
| 0.90% | 4 M€ | +20.04% |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| +1.64% | +0.45% | +22.50% | +81.08% | 9.48B | ||
| -0.52% | +1.04% | +7.72% | -4.88% | 89.24B | ||
| -0.62% | +3.44% | +35.16% | +6.78% | 48.41B | ||
| -0.19% | +1.73% | +152.08% | +93.27% | 37.57B | ||
| -0.10% | +0.46% | -31.04% | -28.35% | 23.44B | ||
| +2.59% | -1.76% | +34.87% | +14.02% | 13.88B | ||
| +2.26% | +7.18% | +56.03% | -35.32% | 13.08B | ||
| -2.15% | +7.07% | +284.99% | +410.84% | 12.18B | ||
| +4.61% | +1.48% | -29.68% | -21.20% | 12.04B | ||
| -2.54% | -0.73% | -55.32% | -64.73% | 9.69B | ||
| Average | +0.50% | +1.22% | +47.73% | +45.15% | 26.9B | |
| Weighted average by Cap. | +0.00% | +0.90% | +42.32% | +27.35% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 25.49B 2.33B 2.21B 2.06B 1.83B 3.28B 198B 3.62B 9.47B 81.04B 8.76B 8.57B 350B | 28.02B 2.56B 2.43B 2.26B 2.02B 3.61B 217B 3.98B 10.41B 89.08B 9.63B 9.42B 385B |
| Net income | 3.51B 321M 305M 284M 253M 452M 27.2B 499M 1.3B 11.16B 1.21B 1.18B 48.21B | 4.87B 446M 423M 394M 350M 627M 37.75B 692M 1.81B 15.49B 1.67B 1.64B 66.92B |
| Net Debt | 14.27B 1.31B 1.24B 1.15B 1.03B 1.84B 111B 2.03B 5.3B 45.37B 4.9B 4.8B 196B | 7.85B 719M 682M 635M 565M 1.01B 60.87B 1.12B 2.92B 24.97B 2.7B 2.64B 108B |
More financial data
* Estimated data
Employees
1,814
Sector
Pharmaceuticals
Calendar
11/12/2024
- Extraordinary Shareholders Meeting
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/12/24 | 309.20 kr | +1.64% | 268,407 |
| 03/12/24 | 304.20 kr | -0.39% | 407,564 |
| 02/12/24 | 305.40 kr | +0.99% | 275,304 |
| 29/11/24 | 302.40 kr | -1.11% | 484,057 |
| 28/11/24 | 305.80 kr | -0.65% | 233,791 |
Delayed Quote Nasdaq Stockholm, December 04, 2024 at 05:00 pm
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
304.20SEK
Average target price
360.64SEK
Spread / Average Target
+18.55%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SOBI Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition